24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
DACTOLIEVA 0.5MG is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | DACTOLIEVA 0.5MG |
|---|---|
| Composition | Dactinomycin for Injection USP 0.5MG |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | Vial |
| Country of Origin | India |
DACTOLIEVA 0.5MG (Dactinomycin for Injection USP 0.5MG) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
DACTOLIEVA 0.5 MG (Dactinomycin for Injection USP 0.5 mg) is a prescription anticancer medicine used in the treatment of various cancers, including Wilms Tumor, Rhabdomyosarcoma, Ewing Sarcoma, Gestational Trophoblastic Neoplasia (GTN), and certain other solid tumors. It contains Dactinomycin 0.5 mg, a potent antineoplastic antibiotic that works by interfering with the DNA of cancer cells, preventing them from growing and multiplying.
Dactinomycin, also known as Actinomycin D, is one of the established chemotherapy medicines used in pediatric and adult oncology. It plays a vital role in combination chemotherapy regimens and is widely utilized in specialized cancer treatment protocols across the world. The medicine helps slow cancer progression by blocking the production of RNA, an essential component required for cell growth and protein synthesis.
Cancer cells divide rapidly and require continuous genetic activity to survive. DACTOLIEVA 0.5 MG targets these abnormal cells by binding directly to DNA and preventing essential cellular processes. This action ultimately leads to cancer cell death and helps reduce tumor growth.
DACTOLIEVA 0.5 MG is commonly prescribed for:
• Wilms Tumor
• Rhabdomyosarcoma
• Ewing Sarcoma
• Gestational Trophoblastic Neoplasia (GTN)
• Gestational Trophoblastic Tumors
• Testicular Cancer (in selected treatment protocols)
• Soft Tissue Sarcomas
• Pediatric Oncology Treatment Programs
• Combination Chemotherapy Regimens
The medicine is often administered as part of a multi-drug chemotherapy plan designed to improve treatment outcomes and enhance disease control. Treatment schedules are individualized according to the type of cancer, disease stage, and patient-specific requirements.
Manufactured under strict pharmaceutical quality standards, DACTOLIEVA 0.5 MG is designed to provide reliable therapeutic performance, safety, and consistency. The injection should only be administered by qualified healthcare professionals in oncology hospitals, cancer centers, or specialized treatment facilities.
Patients receiving Dactinomycin therapy may require routine blood tests, liver function monitoring, kidney assessments, and regular medical evaluations to ensure safe and effective treatment. These assessments help healthcare providers monitor treatment response and manage side effects appropriately.
Due to its established effectiveness in treating several pediatric and adult cancers, DACTOLIEVA 0.5 MG remains an important component of modern oncology treatment protocols.
DACTOLIEVA 0.5 MG (Dactinomycin for Injection USP 0.5 mg) is primarily used for the treatment and management of specific cancers.
The medicine is commonly used in the treatment of Wilms tumor, a kidney cancer that primarily affects children.
Doctors may prescribe Dactinomycin as part of chemotherapy protocols for rhabdomyosarcoma.
DACTOLIEVA may be included in treatment plans for patients diagnosed with Ewing sarcoma.
The medicine is widely used in the management of trophoblastic tumors and related conditions.
Dactinomycin may help control certain cancers affecting muscles and connective tissues.
The medicine is frequently used alongside other anticancer medicines to improve treatment effectiveness.
Dactinomycin belongs to a class of medicines known as Antineoplastic Antibiotics.
DACTOLIEVA works by:
• Binding directly to cancer cell DNA
• Blocking RNA synthesis
• Preventing cancer cell growth
• Inhibiting cell division
• Slowing tumor progression
• Promoting cancer cell death
This targeted mechanism helps control cancer growth and supports effective chemotherapy treatment.
Like all chemotherapy medicines, DACTOLIEVA 0.5 MG may cause side effects in some patients. Side effects vary depending on individual response, treatment duration, and overall health condition.
Patients may experience mild to moderate nausea after treatment.
Episodes of vomiting may occur during chemotherapy.
Weakness, tiredness, and reduced energy levels are commonly reported.
Patients may experience decreased appetite and reduced food intake.
Oral ulcers and mouth irritation may develop during therapy.
Temporary hair thinning or hair loss may occur.
Digestive disturbances and loose stools may develop.
Some patients may experience skin irritation or increased sensitivity.
Dactinomycin may reduce:
• White blood cell counts
• Red blood cell counts
• Platelet counts
This can increase the risk of infections, anemia, and bleeding complications.
Seek immediate medical attention if you experience:
• High fever
• Severe infection symptoms
• Unusual bleeding or bruising
• Difficulty breathing
• Severe allergic reactions
• Persistent vomiting
• Severe abdominal pain
• Liver-related symptoms
• Significant weakness
Patients should immediately contact their healthcare provider if serious symptoms occur.
The dosage of DACTOLIEVA 0.5 MG (Dactinomycin for Injection USP 0.5 mg) should always be determined by a qualified oncologist or healthcare professional.
Dosage depends on the diagnosed cancer and treatment protocol.
Chemotherapy dosage is often calculated according to body size.
Pediatric and adult dosing schedules may differ.
Treatment decisions may depend on laboratory test results.
Doctors may adjust therapy based on effectiveness and side effect management.
• The injection should only be administered by trained healthcare professionals.
• Follow the prescribed chemotherapy schedule carefully.
• Attend all scheduled monitoring appointments.
• Regular blood tests are essential during treatment.
• Inform your doctor about any unusual symptoms.
• Do not alter treatment schedules without medical supervision.
Before receiving treatment, patients should inform their doctor if they have:
• Liver disease
• Kidney disease
• Blood disorders
• Active infections
• Previous chemotherapy complications
• Allergies to medications
Patients should also disclose all prescription medicines, supplements, and herbal products they are currently taking to avoid possible drug interactions.
Pregnant or breastfeeding women should only receive this medicine if specifically recommended by a healthcare professional.
• Store according to manufacturer recommendations.
• Protect from direct sunlight and excessive heat.
• Keep out of reach of children.
• Follow hospital and pharmacy storage guidelines.
• Trusted Dactinomycin formulation
• Effective treatment option for pediatric and adult cancers
• Supports internationally recognized chemotherapy protocols
• Manufactured under strict pharmaceutical quality standards
• Reliable therapeutic performance
• Suitable for modern oncology treatment programs
• Helps support comprehensive cancer care
It is used for the treatment of Wilms tumor, rhabdomyosarcoma, Ewing sarcoma, gestational trophoblastic neoplasia, and certain other cancers.
Dactinomycin is an antineoplastic antibiotic that interferes with cancer cell DNA and helps stop tumor growth.
Yes, it is a chemotherapy medicine used in various oncology treatment protocols.
Yes, Dactinomycin is commonly used in pediatric oncology under specialist supervision.
Yes, treatment may lower white blood cells, red blood cells, and platelets, requiring regular monitoring.
Yes, doctors typically recommend blood tests, liver function assessments, and routine medical evaluations throughout therapy.
No, chemotherapy treatment should only be modified or discontinued under medical supervision.
Yes, this medicine should only be administered by qualified healthcare professionals experienced in oncology and chemotherapy treatment.